Skip to main content
H. Bar-Yoseph on Muck Rack

H. Bar-Yoseph

As seen in: Color Research & Application
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with H.

Contact H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy

|
By H. Bar-Yoseph, L. Brent Selinger, M. Yavzori, O. Picard, E. Fudim, U. Kopylov, R. Eliakim, S. Ben-Horin, Y. Chowers, B. Ungar, N. Levhar, U. Manor
| Color Research & Application Verified
Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined. To evaluate the association of early (week 2 and week 6) induction infliximab and anti-infliximab antibody levels with primary nonresponse.
Open in Who Shared Issue with article?

Editorial: anti-tumour necrosis factor α antibodies - can efficacy be regained?

|
By Y. Chowers, H. Bar-Yoseph
| Color Research & Application Verified
Invited EditorialEditorial: anti-tumour necrosis factor ? antibodies – can efficacy be regained?AuthorsH. Bar-Yoseph,Rambam Health Care Campus, Gastroenterology Institute, Haifa, IsraelSearch for more papers by this authorY.
Open in Who Shared Issue with article?
See all 2 articles